Leading the Charge

We’ve built a company poised to produce transformative pharmaceutical solutions by bringing together leaders steeped in all the functional areas needed to bring new drugs to life. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we’re acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need.

Meet Our Best & Brightest

Bringing products to market for patients with high unmet medical need. Managing quality and regulatory compliance for a global biotech company. Overseeing clinical development for top-flight pharmaceutical companies. These are the back stories of just some of the bright minds you’ll find in the lab, meeting room and beyond at Dova Pharmaceuticals.

Lee F. Allen, M.D., Ph.D.

Lee F. Allen, M.D., Ph.D. Chief Medicial Officer

Dr. Allen has served as our Chief Medical Officer since April 2017. He has over twenty tears of pharmaceutical development experience and has successfully led the development and approval of five new hematology and oncology products. From January 2016 to April 2017, Dr. Allen served as Chief Medical Officer managing Clinical Development, Medical Affairs and Regulatory Affairs at Argos Therapeutics. Dr. Allen served as Chief Medical Officer at Spectrum Pharmaceuticals from March 2013 to January 2016. From August 2007 to March 2013, Dr. Allen served as Chief Medical Officer at AMAG Pharmaceuticals. From 2003 through 2007, Dr. Allen served as the Clinical Site Head and Global Oncology Therapeutic Area Director for Wyeth Pharmaceuticals’ research and development site in Cambridge, MA. From 1999 to 2003, Dr. Allen helped establish Oncology as a new therapeutic area at Pfizer and served as Executive Director and Site Therapeutic Area Leader for the Ann Arbor Oncology portfolio. Dr. Allen holds a Ph.D. and M.D. from the Rutgers Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey), and completed Residency training in Internal Medicine and Fellowship training in Hematology and Oncology at the Duke University Medical Center.